A Study of Two Dosage Forms of LY2886721 in Healthy Participants

Inclusion Criteria: * Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive, at screening * At least 4 participants who are greater than 55 years of age * Male participants: Agree to use a reliable method of birth control and not donate sperm during the study and for 3 months following the last dose of the investigational product * Female participants: Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy, hysterectomy, or both) confirmed by medical history, or postmenopausal females, as determined by medical history and physical examination (spontaneous amenorrhea for 6 to 12 months and a follicle stimulating hormone \[FSH\] level greater than 40 milli-international units per milliliter \[mIU/mL\]) * Have venous access sufficient to allow for blood sampling as per the protocol Exclusion Criteria: * Are currently enrolled in, have completed, or discontinued within the last 30 days from a clinical trial involving an investigational product; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Have participated, within the last 30 days, in a clinical trial involving an investigational product * Have known allergies to LY2886721, related compounds, or any components of the formulation * Have an abnormality in the 12-lead electrocardiogram (ECG) * Have a significantly abnormal blood pressure as determined by the investigator * Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Regularly use known drugs of abuse and/or show positive findings on urinary drug screening * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Show evidence of hepatitis B or C and/or positive hepatitis B or C antibody * Have a history of, or current, significant ophthalmologic disease * Show evidence of significant active neuropsychiatric disease or history of suicide attempt